Abstract
By many measures, the Orphan Drug Act has been a resounding success. Yet many rare diseases still lack treatments, and some manufacturers have used the law in ways that diverge from its original intent.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
